Opioid users breathe easier with novel drug to treat respiratory depression

Respiratory stimulant reverses, prevents opioid-induced adverse event without compromising pain relief

Chicago — (August 19, 2014) 

People taking prescription opioids to treat moderate to severe pain may be able to breathe a little easier, literally.  A study published in the September issue of Anesthesiology, the official medical journal of the American Society of Anesthesiologists® (ASA®), found that a new therapeutic drug, GAL-021, may reverse or prevent respiratory depression, or inadequate breathing, in patients taking opioid medication without compromising pain relief or increasing sedation.

“Although opioids such as oxycodone, methadone and fentanyl are commonly used to manage perioperative and postoperative pain, opioids are associated with an increased risk of adverse effects, the most serious being respiratory depression,” said Albert Dahan, M.D., lead author and professor of anesthesiology at Leiden University Medical Center in the Netherlands.  “Opioid-induced respiratory depression can lead to brain damage, cardiac arrest or death.”

Current drug treatments for opioid-induced respiratory depression (OIRD) include administering a drug such as naloxone that counteracts the effect of the opioid and/or decreasing opioid doses; however, both compromise pain relief.  Conversely, GAL-021 is an intravenous respiratory stimulant that works by blocking certain potassium channels in the brain that regulate breathing.  It has been previously reported that GAL-021 reverses respiratory depression in animals without diminishing opioid-related pain relief.  

In the study, GAL-021 stimulated breathing in 12 healthy male volunteers who underwent opioid-induced respiratory depression, at which time their breathing capacity was decreased by 25 to 30 percent. All patients experienced an increase in respiratory rate and tidal volume, which is the amount of air that is expelled during a normal breath. Researchers also found that GAL-021 had no adverse affect on non-respiratory variables such as sedation, pain relief, blood flow or safety parameters.

“The development of potent painkillers that do not increase the risk of respiratory depression seems still far away,” said Dr. Dahan.  “Using an add-on drug that reverses or prevents respiratory depression caused by opioid use, without affecting pain relief, is currently our best option to treat this condition. While our data suggest that GAL-021 is an attractive alternative to other respiratory stimulants, additional studies are needed to further confirm these findings.”

The Leiden University Medical Center respiratory laboratory is currently funded by some other parties involved in opioid-induced respiratory depression and reversal of respiratory depression: Mundipharma (Cambridge, United Kingdom) and Revive Therapeutics (Vaughan, Ontario, Canada).

THE AMERICAN SOCIETY OF ANESTHESIOLOGISTS

Founded in 1905, the American Society of Anesthesiologists (ASA) is an educational, research and scientific society with more than 52,000 members organized to raise and maintain the standards of the medical practice of anesthesiology. ASA is committed to ensuring physician anesthesiologists evaluate and supervise the medical care of patients before, during and after surgery to provide the highest quality and safest care every patient deserves.

For more information on the field of anesthesiology, visit the American Society of Anesthesiologists online at asahq.org. To learn more about the role physician anesthesiologists play in ensuring patient safety, visit asahq.org/WhenSecondsCount. Join the ANESTHESIOLOGYTM 2014 social conversation today. Like ASA on Facebook, follow ASALifeline on Twitter and use the hashtag #ANES2014.

###

Contact:

American Society of Anesthesiologists
pr@asahq.org
847-825-5586